Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation  by Oran, Betül et al.
Biol Blood Marrow Transplant 21 (2015) 1405e1412Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgClinical Research: AdultAge and Modiﬁed European LeukemiaNet Classiﬁcation to
Predict Transplant Outcomes: An Integrated Approach for
Acute Myelogenous Leukemia Patients Undergoing Allogeneic
Stem Cell TransplantationBetül Oran 1, Antonio M. Jimenez 1, Marcos De Lima 2, Uday R. Popat 1, Roland Bassett 3,
Borje S. Andersson 1, Gautam Borthakur 4, Qaiser Bashir 1, Julianne Chen 1, Stefan O. Ciurea 1,
Elias Jabbour 4, Jorge Cortes 4, Partow Kebriaei 1, Issa F. Khouri 1, Muzaffar H. Qazilbash 1,
Farhad Ravandi 4, Gabriela Rondon 1, Xinyan Lu 5, Elizabeth J. Shpall 1, Richard E. Champlin 1,*
1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
2Department of Medicine, Hematology and Oncology, University Hospitals and Case Western Reserve University, Cleveland, Ohio
3Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
4Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
5Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TexasArticle history:
Received 12 January 2015
Accepted 25 March 2015
Key Words:
AML
European LeukemiaNet
Allogeneic stem cell
transplantation
PrognosisFinancial disclosure: See Acknowle
* Correspondence and reprint req
of Stem Cell Transplantation and Ce
Anderson Cancer Center, 1515 H
TX 77030.
E-mail address: rchampli@mda
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
We evaluated the prognostic signiﬁcance of a modiﬁed European LeukemiaNet (ELN) classiﬁcation for pa-
tients with acute myelogenous leukemia (AML) undergoing hematopoietic stem cell transplantation (HSCT)
while in ﬁrst complete remission (CR1). We analyzed 464 AML patients with matched related (n ¼ 211, 45.5%),
matched unrelated (n ¼ 176, 37.9%), and mismatched donors (n ¼ 77, 16.6%). Patients were classiﬁed into 4
modiﬁed ELN risk groups (favorable, intermediate-I, intermediate-II, and adverse) separately for 354 patients
age < 60 years and 110 patients age  60 years. In this modiﬁed version of ELN classiﬁcation, patients with
normal cytogenetic were classiﬁed by FLT3-ITD mutational status: favorable risk if FLT3-ITDwild and
intermediate-I if FLT3-ITDmut. The best outcomes occurred in the ELN favorable and intermediate-II groups in
younger AML patients and in the favorable and intermediate-I groups in older AML patients. Older AML
patients had worse transplant outcomes within each modiﬁed ELN risk group except intermediate-I when
compared with younger patients; leukemia-free survival at 3 years was 67.8% versus 49.8% in favorable, 53.4%
versus 50.7% in intermediate-I, 65.7% versus 20.2% in intermediate-II, and 44.6% versus 23.8% in adverse
group younger and older patients, respectively. Among lesion-speciﬁc abnormalities, del5q/5 and abnl(17p)
had the worse transplant outcomes, with 3-year leukemia-free survival rates of 18.4% and 20% in younger CR1
patients. In conclusion, the modiﬁed ELN prognostic classiﬁcation developed for chemotherapy outcomes also
identiﬁes prognostic groups for HSCT, which is useful for a selection of patients for post-transplant strategies
to improve outcomes.
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Achieving cure in acute myelogenous leukemia (AML)
depends on successful induction therapy to achieve a com-
plete remission (CR) and subsequent postremission therapydgments on page 1411.
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ty for Blood and Marrow Transplantation.to prevent relapse. A major treatment decision is whether to
recommend allogeneic hematopoietic stem cell trans-
plantation (HSCT) or to continue with consolidation
chemotherapy for patients in ﬁrst CR (CR1). The choice of
therapy is determined by patient and disease factors
affecting the prognosis with each treatment modality. Allo-
geneic hematopoietic transplantation is an effective treat-
ment but carries a higher risk of treatment-relatedmorbidity
and mortality; HSCT is indicated for patients in CR1 when
progression-free survival exceeds that achieved with
conventional chemotherapy. Based on prospective and
Table 1
Standardized Reporting for Correlation of Cytogenetic and Molecular Ge-
netic Data in AML with Clinical Data According to the ELN Guideline
ELN Genetic
Risk Group
Subsets
Favorable t(8;21)(q22;q22); RUNX1-RUNX1T1inv(16)
(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Mutated NPM1 without FLT3-ITD (normal karyotype)
Mutated CEBPa (normal karyotype)
Intermediate-I Mutated NPM1 and FLT3-ITD (normal karyotype)
Wild-type NPM1 and FLT3-ITD (normal karyotype)
Wild-type NPM1 without FLT3-ITD (normal
karyotype)
Intermediate-II t(9;11)(p22;q23); MLLT3-MLL Cytogenetic
abnormalities not classiﬁed as favorable or adverse
Adverse inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-
EVI1t(6;9)(p23;q34); DEK-NUP214t(v;11)(v;q23);
MLL rearranged5 or del(5q); 7; abnl(17p);
complex karyotype
B. Oran et al. / Biol Blood Marrow Transplant 21 (2015) 1405e14121406retrospective studies as well as meta-analyses, patients with
intermediate or high-risk cytogenetics have been considered
candidates for hematopoietic transplantation, whereas
patients with favorable-risk cytogenetics have been recom-
mended to continue with consolidation chemotherapy [1,2].
There has been major progress in deﬁning the molecular
pathophysiology of AML, and molecular subtypes of the
disease have been described that impact prognosis [3]. An
international expert panel, working on behalf of the Euro-
pean LeukemiaNet (ELN), proposed a standardized prog-
nostic system, incorporating both cytogenetic and select
molecular abnormalities, separating AML patients into 4
distinct genetic risk groups [3]. At least 2 studies have
demonstrated prognostic stratiﬁcation when ELN criteria
were applied to large patient cohorts receiving chemo-
therapy, and this prognostic system is being used for treat-
ment planning and clinical trials [4,5]. Adults younger than
age 60 with favorable, intermediate-I, intermediate-II, and
high-risk AML have 3-year progression-free survival rates of
approximately 55%, 23%, 34%, and 10%, respectively, with
chemotherapy. Age is also an independent risk factor in AML.
Older patients can successfully receive reduced-intensity
preparative regimens; patients over age 60 have achieved
favorable outcomes compared with chemotherapy [6].
The outcomes for patients in ELN risk categories and the
impact of age on the transplant outcome in each ELN cate-
gory have not been determined for HSCT. In the present
analyses, we investigated the prognostic signiﬁcance of the
ELN classiﬁcation and age in a large cohort of adult AML
patients who underwent allogeneic HSCT in CR1 at our
institution over the last decade.
METHODS
Patient Population and Transplantation Procedure
We retrospectively analyzed the results of allogeneic HSCT in patients
with AML 18 years or older transplanted in CR1 at the University of Texas
M.D. Anderson Cancer Center between January 1, 2001 and June 30, 2014.
Disease status at HSCT was deﬁned in accordance with previously pub-
lished criteria [7]. Patients with incomplete hematopoietic recovery were
not included in the analyses. The evaluation of comorbidities and as-
signments of scores were done using the consistent deﬁnitions for coding
the 17 components of the hematopoietic cell transplant-comorbidity index
(HCT-CI) [8].
Cytogenetic and Molecular Analyses and Grouping of Patients
Complete cytogenetic information was available in 452 of 464 patients
(97.4%). Assessable patients with diagnostic cytogenetic abnormalities were
evaluated for the presence of speciﬁc chromosomal abnormalities and
complex karyotype (CK) deﬁned as3 cytogenetic aberrations. Core binding
factor (CBF) abnormalities included t(8;21), inv(16)/t(16;16) and high-risk
chromosomal abnormalities included inv3(q21q26.2) or t(3;3)(q21q26.2),
t(6;9)(p23;q34), t(v;11)(v;q23), 5/del5q, 7, and abnormalities involving
17p. Ultimately, patients were assigned to 4 prognostic groups using the ELN
classiﬁcation as published in 2010 [3]: favorable, intermediate-I, interme-
diate-II, and adverse risk (Table 1). Of 174 patients with normal cytogenetics
(CN), FLT3-ITD mutation was assessable in 145 patients (83.3%), NPM1 in 77
patients (44.3%), and CEBPa in 46 patients (26.4%). Seventy-ﬁve CN patients
(43.1%) with both FLT3-ITD and NPM1mutations were assessable. Therefore,
we modiﬁed the ELN classiﬁcation, and prognostic classiﬁcation of CN pa-
tients was determined only by the presence of FLT3-ITD mutation. Patients
with CN were classiﬁed as favorable risk if they had FLT3-ITDwild and
intermediate-I if FLT3-ITDmut.
HSCT Characteristics
Patients with peripheral blood, bone marrow, and cord blood as the
hematopoietic stem cell source were included. Among peripheral blood or
bone marrow recipients, 211 (45.5%) had matched related donors (MRDs)
and 176 (37.9%) matched unrelated donors (MUDs). Five patients (1.1%) had
mismatched related donors, and 27 patients (5.8%) had 1-antigen mis-
matched unrelated donors. Twenty patients (4.3%) received a haploidentical
graft. Because of small sample sizes, recipients of mismatched relateddonors, mismatched unrelated donors, haploidentical donors, and cord
blood units were analyzed together as mismatched donors (MMDs).
The impact of conditioning regimens on outcomeswas analyzed by their
dose intensity, using Center for International Blood and Marrow Transplant
Research criteria [9]. Tacrolimus and methotrexate were used as graft-
versus-host disease prophylaxis in most patients (n ¼ 368, 84.4%).Statistical Analysis and End Point Deﬁnitions
Outcomes analyzed were leukemia-free survival (LFS), cumulative
relapse incidence (RI), transplant-related mortality (TRM), and overall sur-
vival (OS). All outcomes were measured from the time of stem cell infusion.
LFS was deﬁned as survival without leukemia progression or relapse;
patients alive without disease progression or relapse were censored at the
time of last contact. OS was based on death from any cause. Surviving pa-
tients were censored at the time of last contact. Relapse was deﬁned as
leukemia recurrence at any site. LFS and OS were calculated using the
Kaplan-Meier method. Univariate comparisons of all end points were
completed by the log-rank test. Cumulative incidence was used to estimate
the endpoints of RI and TRM. A Cox proportional hazards model [10] or the
Fine and Gray method [11] for competing hazards was used for multivariate
regression. Variables were included in the multivariate model if they were
conceptually important or if they approached (P < .2) or attained statistical
signiﬁcance by univariate analysis. All factors were tested for the propor-
tional hazards assumption. All P values were 2-sided. Analyses were strat-
iﬁed by age at HSCT. The analyses were based on follow-up through
August 2014.
RESULTS
Median age of all patients at HSCT was 52 years (inter-
quartile range [IQR], 40 to 59). This patient population
comprised 354 adults (76.3%) aged less than 60 years and 110
adults (23.7%) aged 60 years or older. Baseline clinical fea-
tures of all patients stratiﬁed as younger and older patients
are presented in Table 2.
Among all 423 assessable patients by modiﬁed ELN, 92
(19.8%) were classiﬁed as favorable, 66 (14.2%) intermediate-
I, 120 (25.9%) intermediate-II, and 145 (31.2%) adverse risk.
The distribution of modiﬁed ELN classiﬁcation among
younger and older patients was similar (P ¼ .09).
In the subgroup of 75 CN patients with both FLT3-ITD and
NPM1 mutations, 9 could be categorized as favorable by ELN
because they had NPM1mut and FLT3-ITDwild. The remaining
66 of 75 patients were intermediate-I by ELN: 27 had
NPM1wild and FLT3-ITDwild, 33 NPM1mut and FLT3-ITDmut,
and 6 had NPM1wild and FLT3-ITDmut. The modiﬁcation of
ELN led to 27 patients (36%) withNPM1wild and FLT3-ITDwild
classiﬁed as favorable rather than intermediate-I risk group.
Of 145 patients with adverse risk by modiﬁed ELN classiﬁ-
cation,7(4.8%)hadinv3(q21q26.2)or t(3;3)(q21q26.2),10(6.9%)
had t(6;9), 26 (17.9%) t(v;11)(v;q23), 59 (40.7%)had5/del5q,46
Table 2
Patient and Disease Characteristics by Disease Status at HSCT
Variable All Patients (n ¼ 464) Age < 60 (n ¼ 354) Age  60 (n ¼ 110) P
n % n % n %
Median age, yr (IQR) 52 (40-59) 47 (35-55) 64 (61-67) .01
Therapy-related AML 74 16 49 13.8 25 22.7 .03
Modiﬁed ELN subsets
Favorable 92 19.8 65 18.4 27 24.6
CBF 13 12 18.5 1 3.7
FLT3-ITDwild 79 53 81.5 26 96.3
Intermediate-1* 66 14.2 47 13.3 19 17.3
Intermediate-2 120 25.9 101 28.3 19 17.3
Adverse 145 31.2 109 31.1 36 32.7 .09
CN/FLT3-ITD-unknown 29 6.2 25 7.1 4 3.6
Cytogenetics-unknown 12 2.6 7 2 5 4.6
CN with FLT3-ITD and NPM1 available 75/174 26/49
NPM1mut FLT3-ITDwild 9 12 6 12 3 12
NPM1mut FLT3-ITDmut 33 44 21 42 12 48
NPM1wild FLT3-ITDmut 6 8 4 8 2 8
NPM1wild FLT3-ITDwild 27 36 19 38 8 32 .9
Lesion-speciﬁc abnormalities within AD 145 109 36
CK 82 56.2
inv3(q21q26.2) or t(3;3)(q21q26.2) 7 4.8 6 5.5 1 2.8 NT
t(6;9) 10 6.9 9 8.3 1 2.8 NT
t(v;11)(v;q23) 26 17.2 23 21.1 2 5.6 .03
del5q/5 59 40.4 39 35.5 20 55.6 .03
7 46 31.5 31 28.2 15 41.7 .1
abnl (17p) 16 11 10 9.2 6 16.7 .2
Cell type
PB 277 59.7 215 60.7 62 56.4
BM 162 34.9 118 33.3 44 40
CB 25 5.4 21 6 4 3.6 .3
Donor type
MRD 211 45.5 164 46.3 47 42.7
MUD 176 37.9 127 35.9 49 44.6
MMD 77 16.6 63 17.8 14 12.7 .2
Conditioning intensity
MAC 376 81 315 89 61 55
RIC 88 19 39 11 49 45 <.001
HCT-CI 430/464 323/354 107/110
0 127 29.5 108 33.4 19 17.8
1-2 122 28.4 96 29.7 26 24.3
3-4 104 24.2 73 22.6 31 39
5 77 17.9 46 14.2 31 29 <.001
Median time to HSCT from diagnosis, mo (IQR) 5.4 (4.2-7.9) 5.2 (4-7.7) 6 (5-8.7)
Year of SCT (after 2008) 274 59 199 56.2 75 68.2 .03
AD indicates active disease; NT, not tested; PB, peripheral blood; BM, bone marrow; CB, cord blood; MAC, myeloablative conditioning; RIC, reduced-intensity
conditioning.
* Intermediate-I included only FLT3-ITDmut patients because the number of patients with NPM1 and FLT3-ITD available were limited.
B. Oran et al. / Biol Blood Marrow Transplant 21 (2015) 1405e1412 1407(31.5%) 7, and 16 (11.1%) had abnl(17p). CK was seen in 82 pa-
tients (56.2%). Within the adverse group, older patients had
more del5q/5 abnormalities (55.6% versus 35.5%, P ¼ .03),
whereas younger patients had more t(v;11)(v;q23) abnormal-
ities (21.1% versus 5.6%, P¼ .03). The distribution of other lesion-
speciﬁc abnormalities including 7, abnl(17p), t(6;9), and CKs
were similar between younger and older patients.
The median time to HSCT was 5.4 months (IQR, 4.2 to 7.9)
and did not differ between modiﬁed ELN risk groups. The
median time to HSCT was 6.4, 5.0, 5.7, and 5.1 months for
favorable, intermediate-I, intermediate-II, and adverse risk
groups, respectively. Median time to HSCT was also similar
for younger and older patients, at 5.2 and 6 months, respec-
tively. Older patients were more frequently transplanted af-
ter 2008, compared with younger patients (P ¼ .03).
Transplant Outcomes by Modiﬁed ELN Classiﬁcation
Overall, 272 of 464 patients were alive at last follow-up,
with a median survival of 37.2 months (IQR, 15.6 to 74). Of
the 272 patients, 249 (91.5%) were alive and free of disease at
their last follow-up. Because of the biological differences andless intensive conditioning regimens received by older
patients, we performed outcome analyses separately for
younger and older patients.
The lowest RI in younger patients was observed in the
favorable and intermediate-II groups with 3-year incidences
of 15.4% and 14.9%, whereas the highest incidence was 39.8%
in the adverse risk group (Table 3, Figure 1). Younger
intermediate-I risk patients with CN/FLT3-ITDmut had a high
RI of 36.5% at 3 years, which was not different from adverse
risk patients (P ¼ .7). The 3-year RIs of 31.1% and 35.5% in
older patients with cytogenetic and molecular features
consistent with favorable and intermediate-II groups by
modiﬁed ELN were approximately twice the 3-year RI
observed in younger patients, although that difference did
not reach statistical signiﬁcance (P¼ .1 and P¼ .06). However,
older patients in intermediate-I and adverse groups had
similar RI with the younger patients.
Younger patients in the favorable and intermediate-II
groups had the longest LFS rates, with 3-year estimates of
67.8% and 65.7%, whereas those in the adverse risk group had
the shortest LFS rates, with an estimate of 44.6%. Patients
Table 3
Outcome Estimates at 3 Years by Modiﬁed ELN in Younger and Older
Patients
Favorable Intermediate-I Intermediate-II Adverse
Younger patients
RI 15.4% 36.5% 14.9% 39.8%
LFS 67.8% 53.4% 65.7% 44.6%
OS 70.4% 57.6% 69.6% 52.9%
Older patients
RI 31.1% 28.5% 35.5% 49%
LFS 49.8% 50.7% 20.2% 23.8%
OS 54.3% 55.3% 19.7% 37.6%
ELN indicates European LeukemiaNet; RI, relapse incidence; LFS leukemia-
free survival; OS, overall survival.
B. Oran et al. / Biol Blood Marrow Transplant 21 (2015) 1405e14121408classiﬁed in the intermediate-I group had a 3-year LFS rate of
53.4%,whichwasnot signiﬁcantly different from the favorable
and intermediate-II groups but was signiﬁcantly better than
those in the adverse risk group (P ¼ .003) (Table 3, Figure 1).
Older patients had 3-year LFS rates of 49.8% and 50.7% in
the favorable and intermediate-I groups, respectively. The
3-year estimates were signiﬁcantly lower in older patients in
intermediate-II and adverse groups, at 20.2% and 23.8%,
respectively. It was striking that older patients had inferior
LFS compared with younger patients in each risk group,
except the intermediate-I group with CN/FLT3mut (Figure 1).
To investigate whether modiﬁed ELN groups remain
associated with transplant outcomes when controlling for
established prognostic factors in AML, we performed multi-
variable analyses. The results revealed that best outcomes in
younger AML patients were observed in favorable and0.
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Figure 1. LFS and OS after HSCT by modiﬁed ELN classiﬁcation in younger and older AM
younger patients, 3-year LFS and OS rates were 67.8% and 70.4% in favorable, 53.4% a
52.9% in adverse risk groups. (C) LFS for patients aged  60. (D) OS for patients aged 
favorable, 50.7% and 55.3% in intermediate-I, 20.2% and 19.7% in intermediate-II, andintermediate-II groups, whereas intermediate-I and adverse
groups represented the worst prognosis (Table 4). In the
younger AML patients, age older than 40 was also associated
with increased RI and decreased LFS and OS. For AML
patients aged 60 or older, multivariate analyses were not
performed for RI, LFS, and OS because no other prognostic
factor for transplant outcomes, other than modiﬁed ELN
classiﬁcation, was identiﬁed in the univariate analyses.
TRM at 1 year was 12.8% in younger and 19.4% in older
patients (P ¼ .05). In younger patients, MMD recipients had
higher TRM with 26.4% compared with 12.9% in MRD re-
cipients (P ¼ .01). No difference was observed between
younger MUD and MRD recipients (P ¼ .5). In older patients,
MUD and MMD recipients had similar TRM as MRD re-
cipients (P¼ .7); failure to detect a difference could be due to
the small sample size of older MMD recipients.
HCT-CI was also able to identify 2 different prognostic
groups for TRM in younger patients. TRM at 1 year was 7.2%
and 11.9% for patients with HCT-CI scores of 0 and 1 to 2,
whereas it was 18.9% and 14.9% in younger AML patients with
scores of 3 to 4 and5, respectively. The differences observed
in 1-year TRM between younger patients with HCT-CI < 3
and 3 were signiﬁcant (P ¼ .02). In older patients, no
prognostic separation with HCT-CI was observed (P ¼ .2).Transplant Outcomes within Modiﬁed ELN Groups
We analyzed the primary outcome of LFS for speciﬁc
subsets within each ELN risk group if there was an adequate
sample size of at least 10 patients.0.
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60. LFS and OS rates at 3 years for patients aged  60 were 49.8% and 54.3% in
23.8% and 37.6% in adverse risk groups.
Table 4
Multivariate Regressions for Transplant Outcomes in Younger Patients
RI* LFSy OSy
HR 95% CI P HR 95% CI P HR 95% CI P
Modiﬁed ELN
IR-I vs. FR 2.7 1.2-6.1 .01 1.8 .97-3.5 .06 1.4 .7-2.9 .3
IR-II vs. FR .99 .4-2.2 .9 1.2 .7-2.1 .5 1.1 .6-2.0 .7
Adverse vs. favorable 3.1 1.6-6.0 .001 2.2 1.3-3.6 .003 2.0 1.2-3.4 .01
Age  40 (yes vs. no) 1.8 1.1-2.9 .02 1.5 1.001-2.1 .049 1.6 1.1-2.4 .03
AML-t (yes vs. no) 1.1 .7-1.7 .8 1.2 .7-1.9 .4
Donor
MUD vs. MRD 1.2 .8-1.7 .3 1.2 .8-1.8 .3
MMD vs. MRD 1.4 .9-2.2 .2 1.6 1.004-2.6 .048
HCT-CI
1-2 vs. 0 1.1 .7-1.8 .6 1.3 .7-2.1 .7
3-4 vs. 0 1.4 .9-2.3 .2 1.9 1.1-3.2 .02
5 vs. 0 1.4 .9-2.3 .2 1.7 1.02-3.0 .04
HR indicates hazard ratio; 95% CI, 95% conﬁdence interval; IR, intermediate risk; FR, favorable risk; AML-t, therapy-related AML.
* Only ELN classiﬁcation and age at HSCT were forced into the model because they were the only variables with signiﬁcance P < .2 at univariate analyses.
y ELN classiﬁcation, age at HSCT, AML-t, donor type, and HCT-CI were forced into the model because they were the only variables with signiﬁcance of P< .2 at
univariate analyses.
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The favorable group bymodiﬁed ELN included 13 patients
with CBF and 76 with CN/FLT3-ITDwild. The indication of
HSCT in CR1 for CBF patients was the presence of high-risk
features, including therapy-related AML, central nervous
involvement at diagnosis, requirement of at least 2 lines of
induction chemotherapy to achieve CR1, and minimal
residual disease by molecular studies after consolidation
chemotherapy. Patients with CN/FLT3-ITDwild were recom-
mended HSCT in CR1 as our institutional policy.
Among younger patients in the favorable group by
modiﬁed ELN, 3-year LFS rates were 71.3% in 12 patients with
CBF and 67.5% in 53 patients with CN/FLT3-ITDwild (P¼ .9). As
indicated, NPM1 mutation analysis was available only in a
subset of patients. Therefore, we modiﬁed the ELN classiﬁ-
cation, and prognostic classiﬁcation of CN patients was
determined only by the presence of FLT3-ITD mutation.
Patients with CN were classiﬁed as favorable risk if they had
FLT3-ITDwild and intermediate-I if FLT3-ITDmut. Of 53
patients classiﬁed in the favorable group by modiﬁed ELN
because they were CN/FLT3-ITDwild, 26 had NPM1 mutation
analysis assessable and 19 would actually be classiﬁed as
intermediate-I risk by ELN because they were FLT3-ITDwild
and NPM1wild. However, the 3-year LFS rate of these 19
patients of 80.5% was comparable with 80.9% in 18 patients
with CBF and CN/FLT3-ITDwild NPM1mut (Supplemental
Table 1). Based on these observations and the limited sam-
ple size of assessable patients with FLT3-ITD and NPM1, we
did not change our classiﬁcation and included all CN/FLT3-
ITDwild in the favorable group for our analyses.
Among older patients classiﬁed as favorable group by
modiﬁed ELN, all 27 patients but 1 had CN/FLT3-ITDwild. The
LFS rate at 3 years was 55.3% and lower compared with
outcome estimates in younger favorable group patients (P ¼
.09). On the other hand, older patients with CN/FLT3-ITDmut
classiﬁed as intermediate-II group by modiﬁed ELN had a
3-year LFS rate of 50.8%, which was comparable with LFS esti-
mates in younger patients (P ¼ .9). We could not perform sub-
group analyses for patientswith FLT3-ITD andNPM1mutations
due to the small sample size in older AML patient with CN.
Intermediate-II group by modiﬁed ELN
Among younger intermediate-II group patients, 23 of 101
(22.8%) had t(9;11)(p22;q23). This group had a 3-year LFSrate of 70.4%, which was comparable with the 3-year LFS rate
of 64.2% (P ¼ .4) in patients with a heterogeneous set of
cytogenetic abnormalities not classiﬁed as favorable or
adverse risk by ELN classiﬁcation.
In 19 older patients with intermediate-II group, only 2
had t(9;11)(p22;q23), and subgroup analyses were not per-
formed because of the small sample size. The 3-year LFS rate
of 20.2% in older patients in the intermediate-II group was
signiﬁcantly lower than the rate of 65.7% seen in younger
patients (P < .001). This striking difference in younger and
older patients is most likely caused by the heterogeneity of
the cytogenetic abnormalities in both age groups.
Adverse Group by Modiﬁed ELN
In the younger adverse group, the 3-year LFS rate was
44.6%.When lesion-speciﬁc abnormalitieswere analyzed, the
presence of 5/del5q and abnl(17p) abnormalities were
found to decrease the primary outcome of LFS signiﬁcantly
(Figure 2A,B). The 3-year LFS rate was 18.4% in 39 patients
with del5q/5 compared with 58.1% in 70 patients without
the abnormality (P< .001). Similarly,10 patientswith abnl17p
had a 3-year LFS rate of 20%, which was inferior to 47.3% in 99
patients without this abnormality (P ¼ .03). The presence
of7did not decrease LFS inyounger adverse risk patients; 3-
year LFS rates of 39.4% in 31 patientswith7was comparable
with 46.8% in patients without 7 (P ¼ .2) (Figure 2C). This
ﬁnding remained the samewhen younger adverse risk group
patients were categorized based on the presence
of 5/del5q, 7, and abnl(17p), as presented in Table 5.
Of 109 younger adverse risk patients, 23 patients with
t(v;11)(v;q23) had a superior 3-year LFS rate of 57.6%
compared with 41.3% in 86 patients without t(v;11)(v;q23)
(P ¼ .06) (Figure 2D), and this was most likely caused by the
exclusive distribution pattern of t(v;11)(v;q23) abnormality.
None of the younger adverse risk group patients with
t(v;11)(v;q23) had other high-risk cytogenetic abnormalities
deﬁned by ELN classiﬁcation. The presence of CK within the
adverse risk groupwas not associatedwith inferior outcomes
(Figure 2E); the 3-year LFS rate of 39.2% in 60 patientswith CK
was comparablewith 51.2% in 49 patients without CK (P¼ .2).
In older adverse risk group patients, only the impact
of 5/del5q, 7, and CK were analyzed because other
lesion-speciﬁc abnormalities were not represented in
adequate sample sizes. At 3 years, the LFS rate was 6.7% in 15
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compared with a LFS rate of 38.7% in 21 patients without 7
(P ¼ .05). Similarly, older adverse risk group patients
with 5/del5 had lower a 3-year LFS rate of 13.9% compared
with 35.2% without 5/del5q, but that difference did not
reach statistical signiﬁcance (P ¼ .1). CK was also associated
with lower LFS with 3-year estimates of 15.9% compared
with 36.7% in adverse risk group patients without signiﬁ-
cance (P ¼ .1).
DISCUSSION
This large single-center study with prolonged follow-up
demonstrated that the modiﬁed ELN classiﬁcation allows
prognostic separation of AML patients, both younger and
older, undergoing allogeneic HSCT. Similar to the experience
with chemotherapy [4,5], modiﬁed ELN classiﬁcation in the
context of allogeneic transplantation was able to effectively
divide younger patients into 2 prognostic groups, with better
outcomes in patients in the favorable and intermediate-II
groups than in the intermediate-I (including CN/FLT3ITD-
mut patients) and adverse groups. In older AML patients,
modiﬁed ELN classiﬁcation was still able to identify 2
different prognostic groups, but the prognostic groups were
different from their younger counterparts. Older AML pa-
tients in the favorable and intermediate-I group had better
outcomes than the intermediate-II and adverse risk groups.
Themodiﬁed ELN classiﬁcationwas predictive for RI, LFS, and
OS in both age groups and was shown to be independent
from other prognostic factors by multivariate analyses.
The most common cause of failure in AML after HSCT
continues to be the relapse of the disease. Accurate charac-
terization of patients at risk of disease recurrence is central to
the design of innovative strategies with the potential to
reduce relapse. The most commonly used risk classiﬁcation
schemas were developed from cooperative efforts of the
Medical Research Council [12], Southwest Oncology Group/
Eastern Cooperative Oncology Group [13], Cancer and
Leukemia Group B [14], and monosomal karyotype catego-
rization of AML patients based only on the cytogenetic in-
formation available [15,16].
The ELN classiﬁcation is an integrated approach,
combining leukemia associated molecular abnormalities
with cytogenetics to provide a more informative character-
ization of prognosis. The ELN classiﬁcation divides patients
into 4 prognostic risk groups, with patients having CN
characterized according to molecular alterations recognized
in the World Health Organization classiﬁcation, namely
NPM1, CEBPA, and FLT3mutations. In our analyses, molecular
information other than the presence of FLT3-ITD mutation
could not be assessed because the information (ie, for NMP1
and CEBPamutations) was not available formost CN patients.
This might lead to categorization of CN patients with
NPM1wild and FLT3-ITDwild as favorable risk rather than
intermediate-I risk, as suggested by ELN, and decrease the
LFS in the favorable risk group in our analysis. However,
CN/FLT3-ITDwild patients (categorized as favorable inFigure 2. LFS by lesion-speciﬁc abnormalities in adverse risk group younger
AML patients after HSCT. Presence of (A) del5q/5 and (B) abnl 17p was
associated with lower LFS. Three-year LFS rates were 18.4% versus 58.1% with
and without del5q/5 (P < .001) and 20% versus 47.3% with and without
abnl17p (P ¼ .03). (C) The presence of 7 did not decrease LFS in younger
adverse risk patients, whereas (D) t(v;11)(v;q23) was associated with superior
3-year LFS within the adverse risk group. (E) The presence of CK within the
adverse risk group was not associated with inferior outcomes.
Table 5
Leukemia-free Survival in Younger Adverse Risk AML Patients by 5/del5q,
7 and abnl(17p)
All Patients
(n ¼ 109)
LFS
n (%) HR 95% CI P
Absence of 5/del5q, abnl(17p)
and 7
54 (49.5) 1.00
Absence of 5/del5q and abnl(17p)
with presence of 7
13 (11.9) 1.5 .6-3.4 .4
Presence of 5/del5q or abnl(17p)
with absence of 7
24 (22) 3.2 1.7-5.8 <.001
Presence of 5/del5q or abnl(17p)
with presence of 7
18 (16.5) 2.7 1.3-5.5 .006
LFS indicates leukemia-free survival; HR, hazard ratio; CI, cumulative
incidence.
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perior LFS compared with CN/FLT3-ITDmut patients who
were categorized as intermediate-I risk group, suggesting the
risk groups might differ with postremission therapy ap-
proaches applied. However, our observation of comparable
outcomes of CN/FLT3-ITDwild with CBF AML after HSCT in
small number of patients needs to be validated in larger
cohorts before it can be widely accepted.
Despite this limitation, which is inherent in retrospective
design analyses, we were able to identify prognostic groups
for transplant outcomes using a modiﬁed ELN classiﬁcation,
conﬁrming the value of combined molecular and cytogenetic
information for risk analyses. We believe that addition of
further genetic markers (eg, DNMT3, TET2, ASXL1, RUNX
mutations, FLT3-ITD allelic ratio) and novel molecular ab-
normalities emerging from next-generation sequencing may
further reﬁne the accuracy of patient risk stratiﬁcation after
transplantation. This information is critical to identify pa-
tients for hematopoietic transplantation and potential post-
transplant therapy strategies to prevent relapse.
We showed that for each modiﬁed ELN risk group, except
the intermediate-I group including CN/FLT3-ITDmut patients,
LFSwasworse forolderpatients comparedwith their younger
counterparts. The prognostic signiﬁcance of the some genetic
alterationsmayvary inyoungerandolderAMLpatients. In our
cohort, older patients had more therapy-related AML, which
independently is a poor prognostic factor. Older patientswere
also more likely to receive a reduced-intensity conditioning
regimen that might lead a higher risk of relapse. Despite the
inferior results in other risk groups, it is notable that for the
intermediate-I group outcome estimates were comparable
with younger patients. There has been considerable debate
about the prognostic signiﬁcance of FLT3-ITD in older patients
with AML [17-19]. Our ﬁndings support the use of allogeneic
HSCT for older patients with FLT3-ITD mutations. The 3-year
LFS rate of 50.7% in older transplanted patients is very
encouraging and signiﬁcantly better than the approximate
20% reported with chemotherapy in this older population
[18]. On the other hand, our older cohort was limited in
number, andour results need tobe conﬁrmed in larger studies
before modiﬁed ELN is accepted as a useful tool for risk clas-
siﬁcation in older transplant patients.
Of particular interest is the effect of cytogenetically spe-
ciﬁc abnormalities on the outcome of ELN risk groups after
HSCT. We observed that HSCT in CR1 was able to overcome
the poor prognosis of adverse risk group younger patients if
they had complex cytogenetics, 7, and t(v;11)(v;q23). On
the other hand, among adverse risk group younger
patients, 5/del5q and abnl17p represented a very poorprognostic subgroup, with 3-year LFS rates of 18.4% and 20%,
respectively, even if transplanted in CR1; this is similar to
previous published reports [20,21]. The inferior outcomes
observed with 5/del5q and abnl17p might be related to
mutations in the p53 gene [22]. In Medical Research Council
AML trials, TP53 mutations were present in 44% of patients
with del(5q) and 66% in patients with a 5, which may
explain the poor outcome in this group [23]. More efﬁcient
treatment strategies to induce p53-independent cell death
are urgently needed.
We could not investigate the chromosome-speciﬁc effect
of other poor-risk cytogenetic abnormalities, including
inv(3)(q21q26.2), t(3;3)(q21q26.2), and t(6;9), because of the
small sample size with these abnormalities. We believe that
collaborative efforts will enable the investigation of outcome
prediction for rare chromosome-speciﬁc abnormalities and
help tailor treatment for these rare abnormalities.
The selection of patients for hematopoietic trans-
plantation requires consideration for the outcomes of stan-
dard chemotherapy and hematopoietic transplantation in
each prognostic group, while also considering the impact of
age, comorbidities, psychosocial factors, and performance
status. A consensus statement by the ELN [24] proposed that
allogeneic HSCT should be favored if projected disease-free
survival is expected to improve an individual’s risk assess-
ment by 10%. In our series, we clearly show that HSCT can
provide long-term disease control in each modiﬁed ELN
group. These data support use of allogeneic HSCT in CR1,
particularly for patients with modiﬁed ELN intermediate-I,
intermediate II, and adverse prognostic groups.
In summary, our results demonstrate clear prognostic
separation among modiﬁed ELN genetic groups for younger
and older AML patients after allogeneic HSCT. Therefore, the
modiﬁed ELN classiﬁcation can possibly be used not only for
predicting post-transplant outcomes but also for stratifying
patients in clinical trials, investigating the role of best post-
remission therapies in AML CR1 patients. It will require
further validation in larger cohorts of patients before being
widely implemented. We believe further studies to assess
the prognostic signiﬁcance of recently deﬁned molecular
abnormalities and minimal residual disease testing will
enable us to better determine prognosis with each form of
treatment and provide an improved basis for selection of
patients for hematopoietic transplantation.
ACKNOWLEDGMENTS
Financial disclosure: U.R.P., B.A., and R.E.C. are recipients of
research funding from Otsuka Pharmaceuticals.
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.
Authorship statement: B.O. and A.M.J. contributed equally
to this study. B.O., A.J., R.B., and R.C. designed the research,
analyzed and interpreted the data, and wrote the article.
M.D.L, U.P., B.A., G.B., Q.B., J.C., S.C., E.J., J.C., P.K., I.K., M.Q., F.R.,
G.R., X.L., and E.S. interpreted the results andwrote the article.
SUPPLEMENTARY DATA
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.bbmt.2015.03.023
REFERENCES
1. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell trans-
plantation for acute myeloid leukemia in ﬁrst complete remission:
systematic review and meta-analysis of prospective clinical trials.
JAMA. 2009;301:2349-2361.
B. Oran et al. / Biol Blood Marrow Transplant 21 (2015) 1405e141214122. Oliansky DM, Appelbaum F, Cassileth PA, et al. The role of cytotoxic
therapy with hematopoietic stem cell transplantation in the therapy of
acute myelogenous leukemia in adults: an evidence-based review. Biol
Blood Marrow Transplant. 2008;14:137-180.
3. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of
acute myeloid leukemia in adults: recommendations from an inter-
national expert panel, on behalf of the European LeukemiaNet. Blood.
2010;115:453-474.
4. Rollig C, Bornhauser M, Thiede C, et al. Long-term prognosis of acute
myeloid leukemia according to the new genetic risk classiﬁcation of the
European LeukemiaNet recommendations: evaluation of the proposed
reporting system. J Clin Oncol. 2011;29:2758-2765.
5. Mrozek K, Marcucci G, Nicolet D, et al. Prognostic signiﬁcance of the
European LeukemiaNet standardized system for reporting cytogenetic
and molecular alterations in adults with acute myeloid leukemia. J Clin
Oncol. 2012;30:4515-4523.
6. Farag SS, Maharry K, Zhang MJ, et al. Comparison of reduced-intensity
hematopoietic cell transplantation with chemotherapy in patients age
60-70 years with acute myelogenous leukemia in ﬁrst remission. Biol
Blood Marrow Transplant. 2011;17:1796-1803.
7. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of
the International Working Group for diagnosis, standardization of
response criteria, treatment outcomes, and reporting standards for
therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:
4642-4649.
8. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation
(HCT)-speciﬁc comorbidity index: a new tool for risk assessment before
allogeneic HCT. Blood. 2005;106:2912-2919.
9. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning
regimen workshop: deﬁning the dose spectrum. Report of a workshop
convened by the center for international blood and marrow transplant
research. Biol Blood Marrow Transplant. 2009;15:367-369.
10. Cox DR. Regression models and life-tables. J R Stat Soc Ser B.
1972;187-220.
11. Fine JP, Gray R. A proportional hazards model for the subdistribution of
a competing risk. J Am Stat Assoc. 1999;94:496-509.
12. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic
cytogenetics on outcome in AML: analysis of 1,612 patients entered
into the MRC AML 10 trial. The Medical Research Council Adult and
Children’s Leukaemia working parties. Blood. 1998;92:2322-2333.
13. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts
outcome of preremission and postremission therapy in adult acutemyeloid leukemia: a Southwest Oncology Group/Eastern Cooperative
Oncology Group Study. Blood. 2000;96:4075-4083.
14. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnor-
malities are predictive of induction success, cumulative incidence of
relapse, and overall survival in adult patients with de novo acute
myeloid leukemia: results from Cancer and Leukemia Group B (CALGB
8461). Blood. 2002;100:4325-4336.
15. Oran B, Dolan M, Cao Q, et al. Monosomal karyotype provides better
prognostic prediction after allogeneic stem cell transplantation in pa-
tients with acute myelogenous leukemia. Biol Blood Marrow Transplant.
2011;17:356-364.
16. Breems DA, Van PuttenWL, De Greef GE, et al. Monosomal karyotype in
acute myeloid leukemia: a better indicator of poor prognosis than a
complex karyotype. J Clin Oncol. 2008;26:4791-4797.
17. Ferrara F, Criscuolo C, Riccardi C, et al. FLT3 mutations have no prog-
nostic impact in elderly patients with acute myeloid leukemia and
normal karyotype. Am J Hematol. 2009;84:532-535.
18. Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem
duplication associates with adverse outcome and gene- and microRNA-
expression signatures in patients 60 years of age or older with primary
cytogenetically normal acute myeloid leukemia: a Cancer and Leuke-
mia Group B study. Blood. 2010;116:3622-3626.
19. Breccia M, Latagliata R, Carmosino I, et al. Negative impact of FLT3
abnormalities in elderly acute myeloid leukemia patients. Leuk Lymph.
2008;49:994-997.
20. Middeke JM, Fang M, Cornelissen JJ, et al. Outcome of patients with
abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem
cell transplantation. Blood. 2014;123:2960-2967.
21. Middeke JM, Beelen D, Stadler M, et al. Outcome of high-risk acute
myeloid leukemia after allogeneic hematopoietic cell transplantation:
negative impact of abnl(17p) and 5/5q. Blood. 2012;120:2521-2528.
22. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute
myeloid leukemia with complex karyotype correlate with speciﬁc copy
number alterations, monosomal karyotype, and dismal outcome. Blood.
2012;119:2114-2121.
23. Bowen D, Groves MJ, Burnett AK, et al. TP53 gene mutation is frequent
in patients with acute myeloid leukemia and complex karyotype, and is
associated with very poor prognosis. Leukemia. 2009;23:203-206.
24. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European Leukemia-
Net AML Working Party consensus statement on allogeneic HSCT for
patients with AML in remission: an integrated-risk adapted approach.
Nat Rev Clin Oncol. 2012;9:579-590.
